Recombinant Mouse CD155/PVR Fc Chimera Protein, CF

When Recombinant Mouse CD96 (Catalog # 5690-CD) is coated at 1 μg/mL, 100 μL/well, Recombinant Mouse CD155/PVR Fc Chimera (Catalog # 9670-CD) binds with an ED50 of 6‑36 ng/mL.

• Reactivity: Mu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Mouse CD155/PVR Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Mouse CD96 (Catalog # 5690-CD) is coated at 1 μg/mL (100 μL/well), the concentration of Recombinant Mouse CD155/PVR Fc Chimera that produces 50% optimal binding response is 6-36 ng/mL.
• Source: Mouse myeloma cell line, NS0-derived mouse CD155/PVR protein
  

  Mouse CD155/PVR (Asp29-Leu348) Accession # NP_081790	IEGRMDP	Mouse IgG2a (Glu98-Lys330)
  N-terminus		C-terminus

• Accession #: NP_081790
• N-terminal Sequence: Asp29
• Structure / Form: DIsulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 62 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 92-108 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Mouse CD155/PVR Fc Chimera Protein, CF

• CD155 antigen
• CD155
• HVED
• NECL5
• Necl-5
• nectin-like 5
• Nectin-like protein 5
• poliovirus receptor
• PVR
• PVS
• PVSFLJ25946
• Tage4

Background

CD155, also known as PVR (poliovirus receptor), Necl-5 (nectin-like molecule-5) and, in rodents, TAGE4 (tumor-associated glycoprotein E4), is a 70-kDa type I transmembrane glycoprotein in the nectin-related family of adhesion proteins within the immunoglobulin superfamily (1, 2). CD155, which may play a role in cancer cell invasion and migration, binds other molecules including Vitronectin, Nectin-3, DNAM-1/CD226, CD96, and TIGIT but does not bind homotypically (3, 4). Mature mouse CD155 consists of a 318 amino acid (aa) extracellular domain (ECD) with one N-terminal V-type and two C2-type Ig-like domains, a 24 aa transmembrane segment, and a 38 aa cytoplasmic tail. Within the ECD, mouse CD155 shares 46%, 73%, and 44% aa sequence identity with human CD155, rat CD155, and mouse Nectin-2, respectively. The V-type domain of CD155 mediates all binding, including to polio virus (1), and alternative splicing within this domain in humans can modulate ligand binding (5). CD155 is up-regulated on endothelial cells by IFN-gamma and is highly expressed on immature thymocytes, lymph node dendritic cells, and tumor cells of epithelial and neuronal origin (1, 2, 6-9). It is preferentially expressed on Th17 cells compared to Th2 cells (10), and its activation promotes the development of Th1 responses (11). Enhanced CD155 expression in tumor cells contributes to loss of contact inhibition and increased migration but also allows tumor cell recognition and killing by DNAM-1 or CD96 expressing NK cells (1, 7, 12). Binding of monocyte DNAM-1 to endothelial cell CD155 promotes transendothelial migration (8). The expression of CD155 on mouse CD8⁺ thymocytes prevents their premature exit from the thymus (13). Within intestinal Peyer's patches, follicular dendritic cell CD155 activates follicular helper T cells via DNAM-1 or CD96 binding (7-9, 14). CD155 also binds the inhibitory ligand TIGIT on NK and some mature T cells, antagonizing DNAM-1 effects (7, 14, 15).

1. Mandai, K. et al. (2015) Curr. Top. Dev. Biol. 112:197.
2. Ravens, I. et al. (2003) Biochem. Biophys. Res. Commun. 312:1364.
3. Sloan, K. et al. (2004) BMC Cancer. 4: 73.
4. Sato, T. et al. (2004) Genes to Cells 9:791.
5. Meyer, D. et al. (2009) J. Biol. Chem. 284:2235.
6. Escalante, N.K. et al. (2011) Arterioscler. Thromb. Vasc. Biol. 31:1177.
7. Xu, Z. and B. Jin (2010) Cell. Mol. Immunol. 7:11.
8. Reymond, N. et al. (2004) J. Exp. Med. 199:1331.
9. Maier, M.K. et al. (2007) Eur. J. Immunol. 37 :2214.
10. Lozano, E. et al. (2013) J. Immunol. 191:3673.
11. Yamashita-Kanemaru, Y. et al. (2015) J. Immunol. 194:5644.
12. Chan, C.J. et al. (2010) J. Immunol. 184:902.
13. Qui, Q. et al. (2010) J. Immunol. 184:1681.
14. Seth, S. et al. (2009) Eur. J. Immunol. 39:3160.
15. Stanietsky, N. et al. (2009) Proc. Natl. Acad. Sci. USA 106:17858.

Publications for CD155/PVR (9670-CD)(3)

Publications using 9670-CD

• Zhong, T;Li, X;Lei, K;Tang, R;Deng, Q;Love, PE;Zhou, Z;Zhao, B;Li, X; TGF-?-mediated crosstalk between TIGIT+ Tregs and CD226+CD8+ T cells in the progression and remission of type 1 diabetes Nature communications 2024-10-15 [PMID: 39406740] (Bioassay, Mouse)
• Jeong, M;Cortopassi, F;See, J;Torre, C;Cerwenka, A;Stojanovic, A; Vitamin A?treated natural killer cells reduce interferon?gamma production and support regulatory T?cell differentiation European journal of immunology 2024-07-01 [PMID: 38593338] (Bioassay, Mouse)
• L Liu, A Wang, X Liu, S Han, Y Sun, J Zhang, L Guo, Y Zhang Blocking TIGIT/CD155 signalling reverses CD8+ T cell exhaustion and enhances the antitumor activity in cervical cancer Oncogene, 2022-06-21;20(1):280. 2022-06-21 [PMID: 35729552] (Bioassay, Mouse)

Bioinformatics

• Uniprot:
  • NP_081790()